Some of the current options for managing COPD include one fixed-dose combination product, as well as combinations with an inhaled steroid, but the experts discuss here why one size does not fit all in terms of treating the inflammation in COPD with steroids.
The panelists note that not all COPD patients are the same, and agree that exacerbators are important, but there may be differentiations in the exacerbators that may ultimately lead to different and better therapies.
The Sanofi/Regeneron PCSK9 inhibitor alirocumab (Praluent)— approved in July in the US — lowered cholesterol in patients with familial hypercholesterolemia to levels “unreachable with statins” researchers said at the European Society of Cardiology meeting in London, UK.
Watch almost any film set in the country of China and at some point the camera will pan past a group of citizens practicing the graceful exercise of Tai Chi. This ancient martial arts practice may look slow, but make no mistake, it's exercise.